At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 59 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers
In Brief
A Phase 1 clinical trial evaluating Pembrolizumab and Radiotherapy for Metastatic Cancers. Completed, enrolled 59 participants across 1 site.
Detailed Summary
Phase I clinical trial of hypofractionated radiotherapy to an isolated index lesion in combination with the PD-1 inhibitor, Pembrolizumab in patients with metastatic cancers who have failed anti-PD-1 therapy (melanoma and NSCLC) and patients with metastatic cancers who have have progressed after at least one regimen of systemic therapy (breast, pancreas, and other).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Cancers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartJan 2015
Primary CompletionDec 2018
Study CompletionDec 2019
TodayJul 2026
First PostedDec 1, 2014
Enrollment StartJan 8, 2015
Primary CompletionDec 1, 2018
Study CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 11.6 years ago
Interventions
Pembrolizumabdrug
Radiotherapyradiation